Target intelligence / Profile preview

Charged multivesicular body protein 2A (CHMP2A)

Target
CHMP2A
Molecular classification
Other (component of ESCRT-III complex), Endosomal sorting complex required for transport protein, Chromatin-modifying protein
01

Overview

Charged multivesicular body protein 2A (CHMP2A) is a core component of the ESCRT-III complex, a multiprotein machinery that enables the formation and maturation of multivesicular bodies (MVBs)—endosomal compartments critical for degrading membrane proteins, sorting cellular cargo, and facilitating receptor downregulation[1][5]. CHMP2A specifically is required for membrane fission processes such as phagophore closure during autophagy, cytokinesis, and nuclear envelope reformation[1][2]. It plays a significant role in regulating autophagic flux and is fundamental to proper lysosomal turnover, with depletion leading to the accumulation of immature autophagosomal structures[2]. Additional evidence links CHMP2A with HIV-1 virus budding, cancer (as a breast adenocarcinoma marker), and neurodegenerative disease. It is regarded as a relevant molecular target for investigating vesicular trafficking, autophagy, and cellular homeostasis[1][2][5].

Other names
Charged multivesicular body protein 2aCHMP2ABC2CHMP2CHMP2aVps2-1hVps2-1BC-2VPS2VPS2AChromatin-modifying protein 2aPutative breast adenocarcinoma marker BC-2Vacuolar protein sorting-associated protein 2-1VPS2 homolog A (S. cerevisiae)charged multivesicular body protein 2aVPS2 homolog Achromatin modifying protein 2Aputative breast adenocarcinoma marker (32kD)
02

Biological functions

Formation and maturation of multivesicular bodies (MVBs)Sorting of endosomal cargo and membrane proteinsAutophagosome membrane closure during autophagyNuclear envelope reformation and mitotic spindle disassemblyMembrane fission in processes like viral budding and cytokinesis
03

Disease associations

Cancer (breast adenocarcinoma)Neurodegenerative disease (Frontotemporal Dementia/Amyotrophic Lateral Sclerosis 7)Infection (involved in HIV-1 virus release)Other (role in autophagy and potentially immune regulation)
04

Safety considerations

Dysfunction affects membrane protein degradation and autophagy, potentially causing accumulation of immature autophagosomes and impacting lysosomal turnover.This could contribute to neurodegeneration or cancer progression.No established therapeutic safety data.
05

Biomarkers

Putative breast adenocarcinoma marker BC-2 (32 kD)

Beyond the preview

Go deeper on Charged multivesicular body protein 2A (CHMP2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Charged multivesicular body protein 2A (CHMP2A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call